Extended Data Table 2 Antitumour activity in LGSOC based on KRAS mutation status

From: Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial

  1. Summary of RECIST v1.1 objective response rate for LGSOC patients by KRAS mutation status, based on confirmed responses only, in the REP population. A response (complete response or partial response) was considered confirmed if two consecutive observations were not less than four weeks apart. Responses not meeting these criteria were considered unconfirmed according to RECIST v1. CI: confidence interval. LGSOC: low-grade serous ovarian cancer. REP: Response evaluable patient.
Back to article page